PAnTHA
A Phase 1 open-label, first-in-human, multi-center study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of 225Ac-PSMA-Trillium in participants with advanced metastatic castration-resistant prostate cancer (mCRPC) Nature and objective :The PAnTHA study aims to assess the safety, tolerance, pharmacokinetics, and preliminary efficacy of 225Ac-PSMA-Trillium, a targeted alpha therapy that is a new class of […]
EvoPar
Double-blind, placebo-controlled, randomized, two-cohort phase III study to evaluate AZD5305 A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician’s Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01) Nature et objective :This is a research project to determine whether the study drug “AZD5305”, given in […]
MK-5684-003
Phase 3, Randomized, Open-Label Trial of MK-5684 Versus Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With a next-generation hormonal agent (NHA) and taxane-based chemotherapy. (MK-5684-003) Nature et objective:This trial is testing MK-5864 in men with metastatic castration-resistant prostate cancer (mCRPC). This trial will compare MK-5684 to abiraterone acetate […]
PROSTEP-002
Detection and monitoring of metastases using PET/CT imaging using the 18F-DCFPyL (PyL) tracer, in patients starting enzalutamide to treat castration-resistant prostate cancer with small number of metastases, an equivocal result or no metastases on conventional imaging (PROSTEP-002). Nature and objective :This is a study for patients with castration-resistant prostate cancer with a small number of metastases. […]
